Last updated on August 2019

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Rheumatoid Arthritis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Diagnosis of RA for >=3 months based on the 2010 ACR/EULAR classification criteria for RA.
  • Participant meets the following minimum disease activity criteria:
  • >=6 swollen joints (based on 66 joint counts) and >=6 tender joints (based on 68 joint counts) at Screening and Baseline Visits
  • hsCRP >=3 mg/L (central lab) at Screening Visit.
  • Participants must have been treated for >=3 months with >=1 bDMARD therapy but continue to exhibit active RA or had to discontinue due to intolerability or toxicity, irrespective of treatment duration.
  • Participants must have been receiving csDMARD therapy >=3 months and on a stable dose for >=4 weeks prior to the first dose of study drug.
  • Participants must have discontinued all bDMARDs prior to the first dose of study drug.

Exclusion Criteria:

  • Participant have prior exposure to any Janus Kinase (JAK) inhibitor for greater than 2 weeks (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib). A washout period of >= 30 days is required for any JAK inhibitor prior to the first dose of study drug.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.